Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
Ufuk Degirmenci(National Cancer Centre Singapore), Jiancheng Hu(Duke-NUS Medical School)
Cited by 536
Related Papers
The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants
|Oncogene|2018|61
BRAF(V600E) mutation together with loss of Trp53 or pTEN drives the origination of hairy cell leukemia from B-lymphocytes
|Molecular Cancer|2023|14
The Dimer-dependent Catalytic Activity of RAF Family Kinases Is Revealed Through Characterizing Their Oncogenic Mutants
|bioRxiv (Cold Spring Harbor Laboratory)|2018|6
Oncogenic non-V600 mutations evade the regulatory machinery of RAF including the Cdc37/Hsp90 chaperone and the 14-3-3 scaffold
|Theranostics|2025|3
AMPKi overcomes the paradoxical activation of CRAF driven by RAF inhibitors through blocking the 14-3-3 binding to its carboxyl-terminus
|bioRxiv (Cold Spring Harbor Laboratory)|2018|0